Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data.

Q3 Medicine Journal of opioid management Pub Date : 2024-07-01 DOI:10.5055/jom.0878
Jody L Green, Taryn Dailey-Govoni, Suzanne K Vosburg
{"title":"Opioid-related clinical outcomes and associated healthcare costs following abuse/misuse of oxycodone formulations: A HEOR analysis from real-world data.","authors":"Jody L Green, Taryn Dailey-Govoni, Suzanne K Vosburg","doi":"10.5055/jom.0878","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: -exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR).</p><p><strong>Study design: </strong>A real-world, observational study.</p><p><strong>Main outcome measures: </strong>Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization.</p><p><strong>Results: </strong>Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER.</p><p><strong>Conclusions: </strong>This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"20 4","pages":"281-288"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of opioid management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5055/jom.0878","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The United States (US) opioid epidemic is a continued burden on the healthcare system and on the lives of individuals affected by the consequences of opioid abuse/misuse. The objective of this study was to use real-world data from intentional abuse/misuse exposures managed by US poison centers to compare clinical outcomes and quantify healthcare costs among three study cohorts: -exposures that involved Xtampza ER®, other oxycodone extended-release (ER), and oxycodone immediate-release (IR).

Study design: A real-world, observational study.

Main outcome measures: Descriptive statistics were used to describe patient and exposure characteristics. Drug utilization-adjusted rates of intentional abuse/misuse and clinical outcomes were used to determine relative risk. Healthcare cost estimates were calculated by extrapolating average charge per opioid-related disorder emergency department (ED) visit and per inpatient stay based upon case disposition rates, adjusted for population and drug utilization.

Results: Compared to Xtampza ER, exposures that involved other oxycodone ER were 7.4 times more likely to be intentional abuse/misuse, 25.9 times more likely to result in major effect or death, 9.7 times more likely to require a visit to the ED, and 14.3 times more likely to result in hospital admission. Similar results were found for oxycodone IR when compared to Xtampza ER.

Conclusions: This study is the first of its kind to synthesize clinical outcomes with opioid-related healthcare costs, suggesting that even when Xtampza ER is abused/misused, the rates of major effect/death, ED visits, and hospital admissions were significantly lower than those for other oxycodone-containing medications, resulting in relatively low downstream opioid-related healthcare costs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
滥用/误用羟考酮制剂后与阿片类药物相关的临床结果和相关医疗费用:对真实世界数据的 HEOR 分析。
目的:美国阿片类药物的流行对医疗保健系统和受阿片类药物滥用/误用后果影响的个人生活造成了持续的负担。本研究的目的是利用美国毒物中心管理的故意滥用/误用暴露的真实数据,比较三个研究队列的临床结果并量化医疗成本:-研究设计:主要结果测量:采用描述性统计来描述患者和暴露特征。采用药物使用调整后的故意滥用/误用率和临床结果来确定相对风险。根据病例处置率推算每次阿片类药物相关疾病急诊就诊和每次住院的平均费用,并根据人口和药物使用情况进行调整,从而计算出医疗成本估算值:与 Xtampza ER 相比,涉及其他羟考酮 ER 的故意滥用/误用可能性高出 7.4 倍,导致重大影响或死亡的可能性高出 25.9 倍,需要到急诊科就诊的可能性高出 9.7 倍,导致住院的可能性高出 14.3 倍。与Xtampza ER相比,羟考酮IR也发现了类似的结果:这项研究首次将临床结果与阿片类药物相关的医疗成本综合在一起,表明即使 Xtampza ER 被滥用/误用,其主要影响/死亡、急诊室就诊率和入院率也明显低于其他含羟考酮的药物,因此阿片类药物相关的下游医疗成本相对较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of opioid management
Journal of opioid management Medicine-Anesthesiology and Pain Medicine
CiteScore
1.00
自引率
0.00%
发文量
54
期刊介绍: The Journal of Opioid Management deals with all aspects of opioids. From basic science, pre-clinical, clinical, abuse, compliance and addiction medicine, the journal provides and unbiased forum for researchers and clinicians to explore and manage the complexities of opioid prescription.
期刊最新文献
A pilot study to examine the opioid prescribing practices of medical residents. Buprenorphine: An anesthesia-centric review. Initial dose of tapentadol and concomitant use of duloxetine are associated with delirium occurring after initiation of tapentadol therapy in cancer patients. Insurance coverage and consistent pricing is needed for over-the-counter naloxone. Naloxone coprescribing best practice advisory for patients at high risk for opioid-related adverse events.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1